UK's IXICO half-year revenue rises 23% on new contracts, margins rise

IXICO

21/04/2026 07:10

Overview

UK neuroscience imaging firm's estimates half-year revenue up 23% yr/yr on new contracts and analysis volume

Gross margin for the half-year expected to rise to 53% from 50%

Order book up 38% yr/yr to £18.1 mln; company completed £10 mln capital raise

Outlook

Company says revenue growth in first half is in line with full-year expectations

IXICO says increased order book provides good visibility of future revenues

Result Drivers

NEW CONTRACTS AND EXTENSIONS - Co said revenue growth was driven by new contract wins, contract extensions and increased biomarker analysis activity

OPERATIONAL LEVERAGE - Gross margin improvement attributed to operational leverage, per CEO Bram Goorden

INVESTMENT IMPACT - EBITDA loss narrowed as increased revenues were partly offset by investments in growth strategy

Company press release: ID:nRSU2090Ba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 3.90 mln
H1 Gross Margin
53.00%
H1 Order Backlog
GBP 18.10 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for IXICO PLC is GBp26.00, about 264.9% above its April 20 closing price of GBp7.13

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)